Hepatic Hemorrhage as a Consequence of Rapid Response to Combined Targeted Therapy in Metastatic Melanoma

Por FLAHERTY, DEVIN C., HOFFNER, BRIANNA W., LAU, BRIANA J., HAMID, OMID, FARIES, MARK B.
Publicado no J Surg Oncol (2015)

Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously u...

Por Puzanov, Igor, Milhem, Mohammed, Andtbacka, Robert, Minor, David, Hamid, Omid, Li, Ai, VanderWalde, Ari, Kaufman, Howard
Publicado em 2013

BM-05 IPILUMUMAB THERAPY FOR MELANOMA BRAIN METASTASES IS ASSOCIATED WITH INCREASED RADIATION NECROSIS

Por Barkhoudarian, Garni, Deutsch, Gary, Yost, Sam, Duong, Huy, Chaloner, Charlene, Eisenberg, Amalia, Boasberg, Peter, Faries, Mark, Hamid, Omid, Kelly, Daniel
Publicado em 2014

Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors

Por Vonderheide, Robert H., Burg, Jennifer M., Mick, Rosemarie, Trosko, Jennifer A., Li, Dongguang, Shaik, M. Naveed, Tolcher, Anthony W., Hamid, Omid
Publicado em 2013

Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma

Por Yan, Yibing, McArthur, Grant, Hamid, Omid, Puzanov, Igor, Gonzalez, Rene, Gajewski, Thomas, Wang, Yulei, Wongchenko, Matthew, Choong, Nicholas, Ribas, Antoni
Publicado em 2014

Regulated intratumoral expression of IL-12 as a basis for combination therapy in melanoma

Por Nemunaitis, John J, Linette, Gerald P, Hamid, Omid, Agarwala, Sanjiv S, Starodub, Alexander, Sun, Lei, Lebel, Francois, Barrett, John A, Lewis, Jonathan
Publicado em 2014

Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF(V600)- mutated melanoma (BRIM7)

Por Puzanov, Igor, McArthur, Grant, Gonzalez, Rene, Pavlick, Anna, Hamid, Omid, Gajewski, Thomas F, Yin, Ming, Fredrickson, Jill, Choong, Nicholas, Ribas, Antoni
Publicado em 2014

A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma

Por Bhatia, Shailender, Pavlick, Anna C., Boasberg, Peter, Thompson, John A., Mulligan, George, Pickard, Michael D., Faessel, Hélène, Dezube, Bruce J., Hamid, Omid
Publicado no Invest New Drugs (2016)

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Por Schadendorf, Dirk, Hodi, F. Stephen, Robert, Caroline, Weber, Jeffrey S., Margolin, Kim, Hamid, Omid, Patt, Debra, Chen, Tai-Tsang, Berman, David M., Wolchok, Jedd D.
Publicado no J Clin Oncol (2015)

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

Por Hamid, Omid, Schmidt, Henrik, Nissan, Aviram, Ridolfi, Laura, Aamdal, Steinar, Hansson, Johan, Guida, Michele, Hyams, David M, Gómez, Henry, Bastholt, Lars, Chasalow, Scott D, Berman, David
Publicado em 2011

A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors

Por Papadopoulos, Kyriakos P, Tsai, Frank, Hamid, Omid, Xiao, Feng, Steele, Keith E, Rebelatto, Marlon C, Robbins, Paul B, Karakunnel, Joyson J, Lai, Dominic W, Mahipal, Amit
Publicado no J Immunother Cancer (2015)

Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma

Por Weber, Jeffrey, Hamid, Omid, Amin, Asim, O’Day, Steven, Masson, Eric, Goldberg, Stacie M., Williams, Daphne, Parker, Susan M., Chasalow, Scott D., Alaparthy, Suresh, Wolchok, Jedd D.
Publicado em 2013

Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials

Por Wolchok, Jedd D., Weber, Jeffrey S., Hamid, Omid, Lebbé, Celeste, Maio, Michele, Schadendorf, Dirk, de Pril, Veerle, Heller, Kevin, Chen, Tai-Tsang, Ibrahim, Ramy, Hoos, Axel, O'Day, Steven J.
Publicado em 2010

Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers

Por Gangadhar, Tara C, Hamid, Omid, Smith, David C, Bauer, Todd M, Wasser, Jeffrey S, Luke, Jason J, Balmanoukian, Ani S, Kaufman, David R, Zhao, Yufan, Maleski, Janet, Leopold, Lance, Gajewski, Thomas F
Publicado no J Immunother Cancer (2015)

Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma

Por Ott, Patrick A., Hamid, Omid, Pavlick, Anna C., Kluger, Harriet, Kim, Kevin B., Boasberg, Peter D., Simantov, Ronit, Crowley, Elizabeth, Green, Jennifer A., Hawthorne, Thomas, Davis, Thomas A., Sznol, Mario, Hwu, Patrick
Publicado no J Clin Oncol (2014)

Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels

Por Leung, Anna M., Lee, Agnes Fermin, Ozao-Choy, Junko, Ramos, Romela Irene, Hamid, Omid, O’Day, Steven J., Shin-Sim, Myung, Morton, Donald L., Faries, Mark B., Sieling, Peter A., Lee, Delphine J.
Publicado em 2014

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer

Por Corcoran, Ryan B., Atreya, Chloe E., Falchook, Gerald S., Kwak, Eunice L., Ryan, David P., Bendell, Johanna C., Hamid, Omid, Messersmith, Wells A., Daud, Adil, Kurzrock, Razelle, Pierobon, Mariaelena, Sun, Peng, Cunningham, Elizabeth, Little, Shonda, Orford, Keith, Motwani, Monica, Bai, Yuchen, Patel, Kiran, Venook, Alan P., Kopetz, Scott
Publicado no J Clin Oncol (2015)

A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States

Por Flaherty, Lawrence, Hamid, Omid, Linette, Gerald, Schuchter, Lynn, Hallmeyer, Sigrun, Gonzalez, Rene, Cowey, C. Lance, Pavlick, Anna, Kudrik, Fred, Curti, Brendan, Lawson, David, Chapman, Paul B., Margolin, Kim, Ribas, Antoni, McDermott, David, Flaherty, Keith, Cranmer, Lee, Hodi, F. Stephen, Day, Bann-Mo, Linke, Rolf, Hainsworth, John
Publicado no Cancer J (2014)

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma

Por Dummer, Reinhard, Daud, Adil, Puzanov, Igor, Hamid, Omid, Schadendorf, Dirk, Robert, Caroline, Schachter, Jacob, Pavlick, Anna, Gonzalez, Rene, Hodi, F Stephen, Cranmer, Lee D, Blank, Christian, O’Day, Steven J, Ascierto, Paolo A, Salama, April K S, Li, Nicole Xiaoyun, Zhou, Wei, Lis, Joy, Ebbinghaus, Scot, Kang, Peter S, Ribas, Antoni
Publicado no J Transl Med (2015)

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

Por Hodi, F. Stephen, Hwu, Wen-Jen, Kefford, Richard, Weber, Jeffrey S., Daud, Adil, Hamid, Omid, Patnaik, Amita, Ribas, Antoni, Robert, Caroline, Gangadhar, Tara C., Joshua, Anthony M., Hersey, Peter, Dronca, Roxana, Joseph, Richard, Hille, Darcy, Xue, Dahai, Li, Xiaoyun Nicole, Kang, S. Peter, Ebbinghaus, Scot, Perrone, Andrea, Wolchok, Jedd D.
Publicado no J Clin Oncol (2016)